Pulmonary arterial hypertension is caused by narrowing of the blood vessels in the lungs. Learn how it happens, including ...

A research team from the Medical University of Vienna has investigated structural changes in kidneys of patients with ...

Strong positive interim data from an earlier Phase 3 trial has led to early cessation of Merck’s pulmonary arterial ...

Pulmonary arterial hypertension (PAH) can be a challenging complication to manage during pregnancy; women with PAH who are ...

A larger diameter of the main pulmonary artery predicts poorer outcomes in pulmonary arterial hypertension (PAH) patients, a ...

Related to PH, healthcare providers may also deal with the diagnosis and treatment of pulmonary arterial hypertension (PAH), a specific type of PH characterized by hypertension (high blood ...

Pulmonary Arterial Hypertension (PAH) is an often-overlooked yet life-altering disease that affects thousands globally, requiring lifelong management, rigorous monitoring, and substantial emotional ...

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor therapeutics to treat pulmonary arterial ...

Liquidia (LQDA) announced that the U.S. Food and Drug Administration has accepted its New Drug Application resubmission for YUTREPIA inhalation ...

Investigators used 4D flow cardiovascular magnetic resonance imaging to search for differences between pulmonary artery (PA) ...